Catenion co-founder and senior partner Markus Thunecke presents the 2023-2024 Biopharma R&D Productivity & Growth Ranking, the latest annual edition of an analysis Catenion started about ten years ago because good perspectives beyond total spending divided by approvals were not available.
Headlines:
- The R&D productivity of the 30 largest public biopharma companies increased by approximately 35% despite a challenging global environment for investment and growth. The increase is mostly driven by the ultra-strong performance of the top five companies versus the rest, a sign of a growing performance divide.
- Mega trends matter: obesity has become the industry’s biggest NPV gainer, followed by oncology, where micro-trends such as antibody-drug conjugates (ADCs), bispecific T-cell engagers, neoantigen-based mRNA vaccination and the CDK4/6 class drive valuations.
Large companies: - Novo Nordisk is number one again thanks to its strength in obesity, but will have to achieve significant growth to satisfy investor expectations.
- Vertex ranks second, with a valuation still largely driven by its cystic fibrosis franchise, and is expanding its portfolio with Casgevy.
- Lilly is third and could become the first pharma company to reach a trillion dollars in market cap, driven largely by tirzepatide in diabetes, obesity and potential future indications.
- Moderna and BioNTech remain in the top 10 (fourth and sixth) but face high uncertainty about the future value of their COVID franchises and may soon drop out of the top 30. Moderna is expanding mRNA into other therapeutic areas, while BioNTech is shifting back to oncology.
- Daiichi Sankyo and AstraZeneca continue their success with Enhertu and their ADC collaboration. The ADC platform has lifted Daiichi Sankyo into the top five and led to a new ADC deal with Merck & Co.
- Regeneron and Amgen return to the top 10 (eighth and ninth) through bispecific antibodies and life cycle management, and Jazz Pharmaceuticals enters the group of the 30 largest companies by sales.
Mid-sized companies (sales rank 31 to 50): several new entrants reach the top 10. Alnylam rises to number one in R&D productivity on its RNA interference platform, two of the top five are driven by strong CNS franchises, and three combine antibody modalities with a strong oncology focus.
Takeaway: biopharma often follows a herd mentality when investing in new science and technology. A hype cycle of trigger event, surge in valuations and fear of missing out rewards only a few companies and leaves marginally differentiated followers struggling. Areas affected today include obesity, artificial intelligence, ADCs and the search for the next big immunology drug. For late entrants, meeting the sky-high expectations built into valuations and deal terms makes meaningful differentiation crucial.



